Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by wildbird1on Nov 06, 2022 11:02am
274 Views
Post# 35077213

RE:RE:RE:RE:Another look at the data

RE:RE:RE:RE:Another look at the dataThe optimized patients effects...

I would not worries to much about the 12 undertreated patients, as more optimized patients are treated, the TR(CR+PR) increase.
TR= number of patients that still have their bladder after TLT cancer treatment.

Exemple, PressRelease AUG 29,2022.
                                                        
                                                             270 day            450 day
Total Response(CR+PR) =                      63 %                 33 %

The 63% of patients that still have their bladder at 270 day include 18 optimized patients. 
Of the 33% of patients that still have their bladder at 450 day, none are optimized patients.

Conclusion 
In DEC 2022, 18 optimized patients will have completed their 450 day data.
Consequently in DEC 2022, the 33% TR at 450 day should climb closer to the 270 day 63% TR results.
The FDA know about the optimized patients effects.

Bode well for the BTD approval.

<< Previous
Bullboard Posts
Next >>